Patent ID: 8129364

Claim:
A formulation for the treatment of fungus-induced rhinosinusitis in a mammal, said formulation comprising an aqueous suspension comprising: a) 0.04% to 0.06% by weight of a suspended solid steroidal anti-inflammatory, wherein the steroidal anti-inflammatory is fluticasone or a pharmaceutically acceptable salt, ester, enol ether, enol ester, acid, or base thereof, said suspended solid steroidal anti-inflammatory having the following particle size distribution profile: i. about 10% of the steroidal anti-inflammatory particles have a particle size of less than 0.4 microns; ii. about 25% of the steroidal anti-inflammatory particles have a particle size of less than 0.8 microns; iii. about 50% of the steroidal anti-inflammatory particles have a particle size of less than 1.5 microns; iv. about 75% of the steroidal anti-inflammatory particles have a particle size of less than 3.0 microns; and v. about 90% of the steroidal anti-inflammatory particles have a particle size of less than 5.3 microns; wherein said formulation is suitable for administration to the nasal-paranasal mucosa; b) from about 0.5 to 150 mg of an antifungal agent; and c) at least at least one complexing agent selected from the group consisting of ethylenediaminetertraacetic acid, citric acid, nitrilotriacetic acid, salts thereof, and sodium edetate.